SCHEMBL6355740

SCHEMBL6355740

CCCS(=O)(=O)NC1CCCC1(O)c1ccc(OCCNC(C)=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
MTNR1A P48039 3/20 0.43
MTNR1B P49286 3/20 0.43
TSHR P16473 2/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ACACB O00763 1/20 0.37
CYP3A4 P08684 1/20 0.36
SLC6A9 P48067 1/20 0.36
PDK2 Q15119 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345791 0.97 ALDH1A1 (0.44) ALDH1A1MTNR1AMTNR1BTSHRUSP2
SCHEMBL6348954 0.89 SLC6A9 (0.45) ALDH1A1TSHRMEN1KMT2ACYP3A4
SCHEMBL6346463 0.89 ALDH1A1 (0.45) ALDH1A1MTNR1AMTNR1BTSHRUSP2
SCHEMBL6345481 0.87 ALDH1A1 (0.42) ALDH1A1TSHRMEN1KMT2ACYP3A4
SCHEMBL6349725 0.86 SLC6A9 (0.44) ALDH1A1TSHRMEN1KMT2ACYP3A4
SCHEMBL6345333 0.86 MEN1 (0.37) ALDH1A1TSHRMEN1KMT2AL3MBTL1
SCHEMBL6357878 0.86 ALDH1A1 (0.44) ALDH1A1MTNR1AMTNR1BTSHRUSP2
SCHEMBL6355737 0.85 MTNR1A (0.44) ALDH1A1MTNR1AMTNR1BTSHRUSP2
SCHEMBL6344428 0.85 ALDH1A1 (0.42) ALDH1A1TSHRMEN1KMT2ACYP3A4
SCHEMBL6356779 0.83 MEN1 (0.39) ALDH1A1TSHRMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP disclosed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 ALDH1A1 642/4885MTNR1A 212/4885MTNR1B 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.